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a  b  s  t  r  a  c  t
Diarrhea  is the leading  cause  of  death  in  neonatal  calves  and  contributes  to major  eco-
nomic  losses.  The  objective  of  this  double-blind  randomized  clinical  trial  was  to evaluate
the effect  of  oral  inorganic  or  organic  zinc  supplementation  as  a treatment  for neonatal
diarrhea in calves.  Seventy  nine  1  to 8 day  old  male  Holstein  calves  on  a California  calf
ranch  were  block  randomized  to one  of  3 treatments  within  24  h from  their  first  onset  of
diarrhea.  Calves  received  a daily  dose  of  either  a placebo  composed  of  80 mg  of  zinc-free
powder,  381.54  mg of  zinc  methionine  (Met)  (equivalent  to 80 mg  of  zinc),  or 99.69  mg  of
zinc oxide  (ZO)  (equivalent  to  80 mg  of  zinc)  in 2 L of  a  zinc-free  oral  rehydration  solution
(ORS).  Calves  were  treated  once  daily  until normal  fecal  consistency  or  for a  maximum  of 14
days.  Upon  enrollment  and  exit,  calves  were  weighed,  and  blood,  feces,  and  liver  biopsies
were collected  for trace  mineral  analysis.  Fecal  samples  at enrollment  and  exit  were  tested
for  E.  coli K99,  Cryptosporidium  spp., rotavirus  and  coronavirus.  Pre-treatment  liver  zinc  con-
centrations  for  the  71  calves  in  the  placebo,  zinc  Met,  and  ZO  treatment  groups  were  710.6
(SEM  =  147.7),  852.3  (SEM  = 129.6),  and  750.7  (SEM  = 202.9)  mg/kg  dry weight  (DW),  respec-
tively.  Exit  liver  zinc  concentrations  for  the  calves  in  the  placebo,  zinc  Met,  and  ZO  treatment
groups were  728.9  (SEM  = 182.9),  1141.0  (SEM  = 423.8),  and  636.8  (SEM  = 81.5)  mg/kg  dry
weight,  respectively.  Although  statistically  non-significant,  there  were  clinically  impor-
tant findings  identified  for  each  of  zinc  Met  and  ZO  treatments.  Calves  treated  with  zinc
Met gained  on  average  40 g/day  during  a diarrhea  episode  compared  to a weight  loss
of 67  g/day  on  average  in  the  placebo-treated  calves  (Power  19.9%).  Calves  treated  with
ZO had  1.4  times  higher  hazard  of  clinical  cure  compared  to calves  in  the  placebo  group
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(Power  5.3%).  Calves  that  were  fecal  positive  to  cryptosporidium  spp.  at enrollment  and
treated  with  zinc  Met  had  higher  odds  of  testing  negative  at  exit  compared  to  placebo
calves (Odds  Ratio  (OR)  =  16.0).  In contrast,  calves  treated  with  ZO  tended  to  recover  (fecal
score  =  1)  one  day  earlier  compared  to  calves  treated  with  a placebo  (8.5 d  vs.  9.7  d).  The  cur-
rent  trial  identified  clinically  important  findings  that  warrant  further  research  to  investigate
effect  fzinc’s  therapeutic  
1. Introduction
Considerable economic losses may  be incurred from
neonatal diseases during calf rearing. In 2006, 8% of
pre-weaned heifers and 2% of weaned heifers died pri-
marily due to diarrhea and other gastrointestinal illnesses
(NAHMS, 2010). Similarly in pediatrics, diarrhea is the lead-
ing cause of death in children under the age of 5 years in
developing countries and is estimated to cause 3 million
deaths annually (Bhutta et al., 2000; Hoque et al., 2009).
In 2004, based on numerous randomized clinical trials,
the World Health Organization recommended zinc supple-
mentation of oral rehydration solutions to decrease the
duration and severity of infant diarrhea (Bhutta et al., 1999;
Faruque et al., 1999; Penny et al., 1999). Infants with diar-
rhea for more than 10 days had significantly lower serum
zinc levels compared to healthy infants or infants with
other non-gastrointestinal illnesses (Naveh et al., 1982),
suggesting gastrointestinal loss of zinc (Hoque et al., 2009).
Zinc-supplemented ORS also resulted in increased recovery
rates, reduced mortality and a reduction in use of antibi-
otics (Bhandari et al., 2008; Bhutta et al., 2000, 1999).
Although the exact underlying mode of action of zinc is still
not known, (Hoque et al., 2009) a mucosal-protective role,
enhanced cell-mediated immunity, and modification of
intra-luminal electrolyte secretion and absorption mech-
anisms have been proposed (Atia and Buchman, 2009;
Fischer Walker et al., 2009; Hoque et al., 2009). Similar
benefits of zinc-supplemented ORS on diarrhea in calves
could significantly impact the economics and sustainability
of the production system by reducing antibiotic use for
treatment of calf diarrhea. Zinc studies have demonstrated
its beneficial effects in piglets and rats, and on calf growth
and fetal development (Graham et al., 2010, 1984; Owusu-
Asiedu et al., 2003). However, the therapeutic use of zinc
in calves with diarrhea has not been studied. A compari-
son of inorganic and organic formulations of zinc such as
zinc oxide (ZO) and zinc methionine (Met), respectively,
is warranted because of differences in zinc bioavailabil-
ity (Wedekind et al., 1992). A greater effectiveness of an
inorganic zinc formulation in treating calf diarrhea com-
pared to an organic formulation may  be evidence of zinc’s
local intra-luminal mode of action given its poor absorption
in the intestines (absorption coefficient of ZO = 0.12 com-
pared to 0.40 for zinc Met) (Cousins, 1985). On the other
hand, if zinc Met  is found to be more effective than ZO
in treating diarrhea this may  be evidence for a systemic
mode of action given the greater bioavailability of zinc Met
compared to ZO. In addition, because zinc is an antago-
nist of copper (NRC, 2001), a comprehensive assessment
of trace minerals is necessary when administering zinc to
calves.or  calf  diarrhea.
© 2013 The Authors. 
 Published by Elsevier B.V. 
The hypothesis of this block-randomized double-blind
clinical trial is that neonatal Holstein calves with diarrhea
supplemented with either zinc Met  or ZO will experience
reduced days to recovery from diarrhea, reduced mortal-
ity, and reduced weight lost during the diarrhea episode
compared to the placebo treated calves. The objective of
this clinical trial was  to compare the effect of a daily dose
of ZO or zinc Met  equivalent to 80 mg  of zinc, or a placebo
for a maximum of 14 days on fecal output and recovery
in otherwise untreated 1 to 8 day-old Holstein bull calves
with neonatal diarrhea on a California calf ranch. A sec-
ondary objective was to assess the effect of zinc Met or ZO
on serum and liver zinc, copper, and iron concentrations.
2. Materials and methods
2.1. Study population
All procedures were approved by the University of
California Davis Institutional Animal Care and Use Com-
mittee (protocol number 16232). The clinical trial was
conducted between June and September 2011 on a large
California calf ranch in the San Joaquin Valley housing
approximately 70,000 Holstein calves, 40,000 of which
were of preweaning age. Calves enrolled included all
male Holsteins that developed diarrhea for the first time
between 1 and 8 days of age. Calves were excluded from
the study if they had a previous incident of diarrhea since
birth or signs of disease other than diarrhea, such as an
umbilical abscess, pneumonia, or meningitis, or if they
were previously treated with antimicrobial drugs. Calves
with diarrhea were identified by a veterinarian (AG) prior
to enrollment.
2.2. Sample size estimation
Due to lack of estimates in neonatal calves, the sam-
ple size estimation was  based on the difference between
serum zinc levels of infants with and without diarrhea. The
increase in serum zinc levels post treatment in calves was
assumed to be similar to that in infants (Naveh et al., 1982).
Hence the sample size was  calculated to detect a statis-
tically significant difference in serum zinc concentrations
in treated calves (mean ± SD, 87 ± 20 g/dl) and placebo
calves (100 ± 14 g/dl) with a power of 80% and level of sig-
nificance of 5%. A total of 22 calves per group were required.
Allowing for a 15% loss to follow-up, a total of 26 calves per
group (n = 78 total) were required in the study.
Open access under CC BY-NC-ND license.2.3. Study design and zinc administration
Prior to initiation of the study, zinc concentrations of
water, calf starter grain, milk replacer, and electrolyte
340 A.D. Glover et al. / Preventive Veterinary Medicine 112 (2013) 338– 347
Table 1
Baseline clinical parameters (rectal temperature, weight, and attitude) of neonatal Holstein calves at enrollment (prior to treatment) into one of the three
treatment groups (placebo, zinc methionine (Met), or zinc oxide (ZO)) from a double-blind block-randomized clinical trial on the effect of zinc as a treatment
for  diarrhea.
Variable Treatmenta,b
Placebo Zinc Met  ZO
N Mean SEM 95% C.I. Mean SEM 95% C.I. Mean SEM 95% C.I.
Lower Upper
Rectal temperature (◦C) 71 38.55 0.12 38.30 38.79 38.80 0.10 38.61 39.00 38.42 0.12 38.19 38.68
Weight (kg) 72 42.34 0.98 40.32 44.36 41.34 1.18 38.90 43.78 42.62 1.08 40.37 44.89
Attitudec 74 1.04 0.04 0.96 1.12 1.08 0.05 0.97 1.19 1.04 0.04 0.95 1.13
a Treatment: Placebo = zinc-free oral rehydration solution (ORS); zinc Met  = 80 mg of zinc/2 L of ORS (381.5 mg of zinc Met); ZO = 80 mg of zinc/2 L of ORS
(99.7  mg  of ZO).
b No significant differences in means within the same row (P < 0.05).
c Attitude Scores: 1 = calf was standing, bright, alert, responsive, and had a good suckle reflex; 2 = calf stood only after stimulation and had a moderate
suckle  reflex; 3 = calf was recumbent, did not stand with stimulation, and had a weak or absent suckle reflex.
Table 2
Fecal zinc, serum zinc, and liver zinc, copper, and iron, concentrations expressed as means in neonatal Holstein calves before and after treatment with
placebo, zinc methionine (Met), or zinc oxide (ZO) from a double-blind block-randomized clinical trial on the effects of zinc as a treatment for diarrhea.
Samplec Pre/Post N Treatmentsa,b
Placebo Zinc Met  ZO
Mean SEM 95% C.I. Mean SEM 95% C.I. Mean SEM 95% CI
Lower Upper
Fecal  zinc Pre 71 135.9 A 17.0 100.9 171.0 153.6 A 21.9 108.5 198.8 153.0 A 14.1 123.6 182.3
Post  71 378.4 A 48.2 278.4 478.5 1128.9 B 255.5 601.5 1656.3 651.3 AB 53.4 540.5 762.0
Serum  zinc Pre 71 0.95 A 0.04 0.87 1.03 0.91 A 0.04 0.82 1.00 0.91 A 0.07 0.76 1.05
Post  71 1.09 A 0.05 0.99 1.19 1.28 B 0.05 1.18 1.39 1.16 AB 0.05 1.05 1.26
Liver  zincd Pre 71 710.6 A 147.7 405.2 1016.1 852.3 A 129.6 585.4 1119.1 750.7 A 202.9 327.5 1173.9
Post  68 728.9 A 182.9 349.6 1108.3 1141.0 A 423.8 264.2 2017.7 636.8 A 81.5 466.9 806.8
Liver
copper
Pre  73 483.9 A 51.3 378.1 589.8 500.4 A 68.9 358.6 642.3 477.3 A 59.8 353.0 601.6
Post  70 683.0 A 119.7 435.3 930.7 741.7 A 211.5 304.2 1179.1 468.1 A 63.5 336.1 600.0
Liver  irond Pre 71 381.7 A 72.4 232.2 531.2 363.3 A 65.9 227.6 499.1 205.9 A 33.3 136.3 275.5
Post  68 347.3 A 90.6 159.9 534.6 254.1 A 46.5 157.9 350.3 157.7 A 24.4 106.7 208.8
a Treatments: Placebo = zinc-free oral rehydration solution (ORS); zinc Met  = 80 mg of zinc/2 L of ORS (381.5 mg of zinc Met); ZO = 80 mg of zinc/2 L of
ORS  (99.7 mg  of ZO).
b Means with different letters within each row are significantly different (P < 0.05).
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M.  Calves were randomized by a veterinarian (AG) to
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ata recording were performed by AG while being blinded
o the true treatments until completion of the trial. Success
f blinding and randomization at producing comparable(mg/kg of DW).
 were insufficient for accurate zinc or iron determination in two samples.
analysis.
groups was  evaluated by comparing baseline values at
enrollment using ANOVA for clinical parameters (Table 1)
and trace mineral concentrations (Table 2). Calves received
a single daily oral dose of either 99.69 mg  of a zinc-free
placebo (electrolyte powder used to make ORS; group 1),
381.54 mg  of zinc Met  (equivalent to 80 mg  of zinc; group
2), or 99.69 mg  of ZO (equivalent to 80 mg  of zinc; group
3) dissolved in 2 L of a zinc-free ORS solution. The dose
of 80 mg  zinc per day was based on the ratio of human
zinc nutrient requirement (NHMRC, 2005) to zinc supple-
mentation of ORS (1:6.7) (Bhandari et al., 2008; Bhutta
et al., 1999; Patel et al., 2009). This was verified to be less
than the ratio in calves of recommended zinc intake (NRC,
2001) to toxic levels (1:37.5) (Graham et al., 1988, 1987b).
2.4. Data collectionUpon enrollment, each calf was weighed (kg;
Salter Brecknell PS-500 scale, Fairmont, MN) and
received a complete physical examination. As part
of the physical examination the rectal temperature
terinaryA.D. Glover et al. / Preventive Ve
(◦C), fecal consistency, and attitude were scored for
each calf. Fecal output was scored by a single vet-
erinarian (AG) after adapting fecal scores from the
University of Wisconsin’s calf health scoring chart
(http://www.vetmed.wisc.edu/dms/fapm/fapmtools/8calf/
calf health scoring chart.pdf). A fecal sample that was
solid, semi-formed/loose, or watery was assigned 1, 2 or
3, respectively. A decision was made to merge the original
chart’s semi-formed and loose categories for consistency
given the potential for difficulty distinguishing between
both on the raised slatted wooden floors of calf hutches.
A similar simple scoring system for calf attitude was
followed. A calf with an attitude score of 1 was standing,
bright, alert, responsive and had a good suckle reflex; a
score 2 calf stood only after stimulation and had a moder-
ate suckle reflex; and a score 3 calf was recumbent, did not
stand with stimulation and had a weak or absent suckle
reflex. After enrollment, fecal consistency and attitude for
all trial calves were recorded every other day. Fecal and
venous blood samples were collected at enrollment, every
other day thereafter, and at exit from trial. In addition,
a liver biopsy (Swanson et al., 2000) was collected from
each calf at enrollment and exit. Calves enrolled were
followed up every other day (physical exam, blood and
fecal samples collected) and continued receiving their
allocated treatment until clinical signs resolved (normal
rectal temperature, no diarrhea for 24–48 h, and attitude
score of 1) or for a maximum of 14 days at which time
calves were eligible for exit.
2.5. Liver biopsy procedure
The liver biopsy was collected as described elsewhere
(Swanson et al., 2000). Briefly, hair was removed from the
ribs between the 10th and 13th right intercostal space. The
site was disinfected using povidone iodine scrub, alcohol
and povidone iodine solution. The incision site was blocked
with 2 ml  of 2% lidocaine using an 18 gauge 1 ½ inch nee-
dle into the skin and thoracic muscles. A stab incision was
made with a carbon steel #15 surgical blade approximately
10 cm from the dorsal midline between the 11th and 12th
intercostal space. A 14 gauge 15 cm sterile CareFusion Tru-
Cut biopsy needle (San Diego, CA) was inserted through
the incision and a liver biopsy was collected. A rapid act-
ing adhesive was used for skin closure. The liver biopsy
was immediately placed into a 2.0 ml  locking-lid micro-
centrifuge tube with polypropylene snap-cap and stored
on ice for a period no more than 3 h before being stored at
−80 ◦C until submission to the testing at the participating
laboratory.
2.6. Blood collection
Blood was collected from the jugular vein using a
20 gauge 1 ½ inch needle and placed into 3.0-ml tubes
(BD Vacutainer, Franklin, NJ) that either contained K2-
EDTA to assess packed cell volume (PCV) and total plasma
protein (TPP) concentration, or specialized trace element
tubes (royal blue top tubes; RBTT) for trace mineral
analysis. Sample PCV (%) was measured using micro-
hematocrit centrifugation, and TPP (g/dl) was measured Medicine 112 (2013) 338– 347 341
using a Reichert-Jung Refractometer. The trace element
blood tubes were spun in a centrifuge for 10 min, serum
decanted into a 2.0 ml  locking-lid microcentrifuge tube
with polypropylene snap-cap and stored at −80 ◦C. Fecal
samples were placed in a sterile 50-ml polypropylene cen-
trifuge tube and stored at −80 ◦C. All fecal and serum
samples were tested within 3 months from collection.
2.7. Sample analyses
2.7.1. Infectious disease testing
Fecal samples collected at enrollment and exit were
tested at the Dairy Epidemiology Laboratory, VMTRC for
Cryptosporidium spp. oocysts, bovine rotavirus and corona-
virus, and E. coli K99 using a commercial kit that is highly
specific (greater than 90%) and sensitive (coronavirus, 77%;
E. coli K99, 93%; rotavirus, 100%) (Biovet, Quebec, Canada)
(Robert et al., 1990; Thorns et al., 1992). Fecal samples were
not initially tested for Salmonella due to a historically low
prevalence of Salmonella in bi-monthly screening routinely
conducted on the study calf ranch.
2.7.2. Necropsy and tissue collection
Calves that died during the study were necropsied to
determine the cause of death. Toxicological tests were
conducted at California Animal Health and Food Safety
(CAHFS) Laboratory in Davis, CA. For heavy metal analy-
sis of liver samples, approximately 0.5 g (biopsy) or 50 g
(carcass) of liver were placed into a sterile plastic Nasco
Whirl-Pak (Thermo Fisher Scientific Inc., Wilmington, MA)
and stored at −80 ◦C until analysis. Tissue samples were
shipped frozen to the CAHFS Toxicology Laboratory. In
order to determine percent of moisture, tissue samples
were placed in a drying oven at 95 ◦C and weighed daily
until constant weight indicated complete removal of mois-
ture.
2.7.3. Trace mineral analysis: liver
Liver samples were digested with nitric acid and
analyzed for lead, manganese, iron, mercury, arsenic,
molybdenum, zinc, copper, and cadmium by inductively
coupled argon plasma emission spectrometry (ICA-PES;
ARL, Accuris Model, Thermo Optek Corporation, Franklin,
MA). Accuracy of ICA-PES was measured by analyzing
standard reference materials (SRM) such as bovine liver
(National Bureau of Standards and Technology, SRM 1577b)
and lobster hepatopancreas (National Research Council of
Canada TORT-2). Data were accepted if values for standard
reference material fell within 2 standard deviations of
the certified reference value. Metal concentrations were
determined on a wet  weight basis and converted to concen-
trations per dry weight by dimensional analysis as follows,
heavy metal in mg/kg dry mass = heavy metal in mg/kg wet
weight × [100/(100 − % moisture)]. Calves were excluded
from liver mineral analysis if the liver biopsy submitted
was less than 5 mg  of wet weight.2.7.4. Trace mineral analysis: feed samples
Feed samples (DM) were digested with nitric acid and
analyzed for lead, manganese, cadmium, copper, iron, zinc,
molybdenum, arsenic, and mercury by ICA-PES. Accuracy of
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CA-PES results was measured by analyzing SRM and over-
piked feed samples of similar matrix. The SRM included
ogfish liver (National Research Council of Canada, DOLT-
) and lobster hepatopancreas (National Research Council
f Canada, TORT-2). Data were accepted if analyzed SRM
alues were within 2 standard deviations of the certified
eference values and over-spike recovery was 80–120%.
.7.5. Trace mineral analysis: serum
Zinc, copper, iron, magnesium, sodium, phosphorus,
alcium and potassium concentrations were measured in
erum samples after precipitation of proteins by using ICA-
ES (FISONS, Accuris Model, Thermo Optek Corporation,
ranklin, MA). Accuracy of ICA-PES results for these ele-
ents was measured by analyzing quality assurance sera
btained from the Veterinary Laboratory Association Qual-
ty Assurance Program (Genzyme Diagnostics, Blaine, MD,
SA). Data were accepted if analyzed quality assurance
erum values were within 2 standard deviations of the ref-
rence values.
.8. Statistical analysis
Statistical analyses were performed using IBM SPSS
tatistics software (version 21; Somers, NY) and STATA
P 11.2 (College Station, TX). Statistical differences were
etermined at the 5% level of significance using intention
o treat analysis.
.8.1. Baseline comparisons
An ANOVA was used to compare calves enrolled in each
reatment group prior to administration of the first treat-
ent with respect to rectal temperature (◦C), weight (kg),
ttitude scores, and fecal, serum, and liver zinc, copper, and
ron concentrations.
.8.2. Mean daily weight change
An ANOVA was used to compare mean daily weight
hange (g) between treatment groups. The mean daily
eight change was calculated as the difference between
xit and enrollment weights divided by number of days a
alf was on the trial.
.8.3. Fecal zinc, serum zinc, and liver zinc, copper, and
ron concentrations at exit
An ANOVA was used to compare calves in each treat-
ent group at exit from the trial with respect to the mean
oncentration of fecal zinc (mg/kg dry weight, DW), serum
inc (mg/L), and liver zinc, copper, and iron (mg/kg DW).
.8.4. Clinical cure
Kaplan–Meier analysis was used to determine mean
ays to a clinical cure for calves that tested positive on fecal
LISA kit at enrollment (Cryptosporidium spp., E. coli K99,
oronavirus, or rotavirus) and had a normal fecal score of 1
or at least 24 h. Calves that died or had a fecal score greater
han 1 at exit were censored.Cox Proportional Hazard (PH) regression analysis was
sed to estimate and compare the hazard for clinical cure as
ssessed every other day. The proportional hazard assump-
ion that clinical cure hazard is independent of time was Medicine 112 (2013) 338– 347
assessed using the log-minus-log (LML) survival plots gen-
erated for each of the treatment group variables with the
placebo group as the reference. The full Cox model for the
hazard of a clinical cure in a calf enrolled with diarrhea can
be summarized as:
(t, X(t)) = 0(t)e
∑v1
i=1ˇXZM+ˇXZO ,
where 0 is a non-negative unspecified baseline hazard,
independent variables (v1) composed of ˇi, the regres-
sion coefficients estimates for ZM (zinc Met) and ZO,
each compared to the placebo, and Xi are their respective
observed covariate values. Cox proportional hazard regres-
sion models were estimated for clinical cure by pathogen
at enrollment. Power calculations were performed for
non-significant models using the global logrank test and
assuming a 5% level of significance, baseline cumulative
failure probabilities observed in the placebo group, and
model estimates for the hazard ratios of the independent
variables (Barthel et al., 2006).
2.8.5. Microbiological cure
Only enrollment and exit fecal samples were tested
for pathogens making the exact time to microbiologi-
cal cure unknown. Hence, logistic regression was used
to estimate and compare the odds of microbiological
cure at exit (fecal score = 1 or 14 days of treatment) for
each treatment group. Microbiological cure was deter-
mined if a calf tested negative for all four pathogens
at exit (E. coli K99, Cryptosporidium spp., coronavirus or
rotavirus). In addition, logistic regression models were esti-
mated for microbiological cure by pathogen at enrollment.
Power calculations were performed for models with non-
significant coefficients assuming a 5% level of significance
and the observed sample sizes and proportion of calves that
attained the respective outcome modeled.
3. Results
A total of 79 calves were enrolled with 26 calves in
group 1 (placebo), 28 calves in group 2 (zinc Met), and 25
in group 3 (ZO). All the trial calves drank their morning
and afternoon two quart daily milk bottles except for two
of the calves that died. The enrollment blocks added up
to 78 calves. In addition a calf was  enrolled in group 2 on
the last day bringing the total enrolled to 79 calves. A total
of 5 calves were excluded from all analyses including: (1)
one calf mistakenly enrolled in group 1 with normal fecal
consistency; (2) two  calves in group 2: one died immedi-
ately after enrollment and its necropsy revealed abomasal
torsion; another was enrolled with an umbilical abscess;
(3) two  calves in group 3: one died after enrollment and
necropsy revealed serous atrophy of fat, and the other
was  moribund at enrollment with severe systemic illness
unable to drink milk or electrolyte treatment.
Of the 74 calves in the study, 3 died during the trial: (1)
one in group 1 (placebo) with gross lesions of an infarct
and perforating ulcer in the cecum; (2) one in group 2 (zinc
Met) with enteritis; (3) one in group 3 (ZO) with bilateral
bronchopneumonia. There was  no evidence of peritoni-
tis associated with the liver biopsies in any of the calves
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Fig. 1. Means and 95% confidence intervals for daily weight change
(grams) in neonatal Holstein calves diagnosed with diarrhea and ran-
domly allocated to a placebo, zinc methionine (Met), or zinc oxide (ZO)
treatment in a double-blind block-randomized clinical trial to study the
effect of zinc as a treatment for diarrhea.
submitted for necropsy. Histology of the formalin-fixed
pancreas of each calf that died revealed no damage to the
exocrine pancreas, and therefore, no evidence of zinc tox-
icosis (Gabrielson et al., 1996, Smith and Embling, 1993).
The remaining 71 calves were treated once daily with either
a placebo, zinc Met, or ZO formulations and were removed
from the trial when they developed a normal fecal score of
1, or at the end of a 14 day supplementation period.
3.1. Baseline comparisons
Baseline comparisons between the 3 treatment groups
at enrollment showed no significant differences in rec-
tal temperature (◦C) (P = 0.06), enrollment weight (kg)
(P = 0.65), or attitude (P = 0.82) (Table 1). There were
no statistically significant differences between fecal zinc
(P = 0.74), serum zinc (P = 0.84), liver zinc (P = 0.80), cop-
per (P = 0.96) or iron (P = 0.13) concentrations at enrollment
(Table 2).
3.2. Mean daily weight change
Weight data for 71 calves at enrollment and exit was
available for analysis. There were no statistically signifi-
cant differences in mean daily weight change for calves
in the three treatment groups (P = 0.33). However, calves
treated with zinc Met  experienced a mean daily weight gain
of 40.24 g (SD = 374.52) compared to a mean daily weight
loss of 66.88 g (SD = 296.16) in the placebo group, or mean
daily weight loss of 85.45 g (SD = 245.27) in the ZO group
(Fig. 1). The power (1 − ˇ) estimate for the comparison of
the mean daily weight loss in the placebo group to the mean
daily weight gain in the zinc Met  was 19.9%. We  estimate a
sample size of 213 calves per group required to find a statis-
tically significant difference using an  ˛ = .05 and a  ˇ = 0.10
(power of 90%).
3.3. Fecal zinc, serum zinc, and liver zinc, copper, and
iron concentrations at exit
Data for 71 calves was available from fecal and serum
zinc, copper, and iron analysis at exit. Data for 3 calves Medicine 112 (2013) 338– 347 343
did not exist because they died during the trial and serum
and fecal samples were not able to be collected prior to
death. At exit, there were no significant difference among
calves in the three treatment groups regarding fecal cop-
per (P = 0.67) and iron (P = 0.16). At exit, calves treated
with zinc Met  had a significantly higher fecal zinc con-
centration (1128.87 mg/kg DW,  P < 0.01) when compared
to the placebo calves, and there were no significant differ-
ences among calves supplemented with zinc Met  and ZO
(P = 0.12; Table 2).
At exit, there were no significant differences among
calves in the three treatment groups regarding serum cop-
per (P = 0.64) and iron (P = 0.90). Calves treated with zinc
Met  had significantly higher serum zinc concentrations
compared to the placebo group (1.28 mg/L vs. 1.09 mg/L,
P = 0.02), and there were no significant differences among
calves treated with zinc Met  and ZO (P = 0.24; Table 2).
Liver zinc analysis results existed for 71 calves at enroll-
ment. Three calves died during the trial, thus there were
only 68 calves available for liver zinc analysis at exit.
Calves that died were necropsied and did not have any
gross or histopathological signs suggestive of overexpo-
sure to zinc (Gabrielson et al., 1996, Smith and Embling,
1993). Liver zinc DW concentrations in calves treated with
zinc Met  or ZO did not differ significantly from calves
treated with a placebo (P = 0.41). The mean (SEM) DW liver
zinc concentrations at exit for the placebo, zinc Met  and
ZO groups were 728.9 (182.9), 1141.0 (423.8), and 636.8
(81.5) mg/kg, respectively. Calves treated with zinc Met  had
64% higher DW liver zinc mean concentrations compared to
the placebo group, although it was not significantly higher
(P = 0.41; Table 2).
Copper liver concentrations were available for 73 calves
at enrollment and 70 calves at exit. Three calves died during
the trial and thus their liver biopsy samples were not avail-
able for analysis at exit. The remaining calves had less than
5 mg  tissue mass biopsied and hence were missing liver
heavy metal concentration at exit. The mean (SEM) DW
liver copper concentrations at exit for the placebo, zinc Met,
and ZO groups were 683.0 (119.7), 741.7 (211.5), and 468.1
(63.5) mg/kg, respectively. There were no significant differ-
ences between the three groups regarding liver copper DW
concentrations at exit (P = 0.41; Table 2).
Liver iron concentrations were available for 71 calves
at enrollment and 68 calves at exit. Three calves died dur-
ing the trial and thus there liver biopsy samples were not
available for analysis at exit. Likewise, the mean (SEM)
DW liver iron concentrations at exit for the placebo, zinc
Met, and ZO groups were 347.3 (90.6), 254.1 (46.5), and
157.7 (24.4) mg/kg, respectively, and there were no signifi-
cant differences in liver iron DW concentrations among the
three treatment groups at exit (P = 0.13; Table 2).
3.4. Clinical cure
A total of 74 calves were included in the Kaplan–Meier
survival analysis for mean days to a clinical cure. There
were no significant differences in mean days to recovery
between calves treated with either the placebo, zinc Met,
or ZO (9.7, 9.7, 8.5), respectively; P = 0.21).
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Table 3
Cox Regression model results from a double-blind block-randomized clinical trial on the effect of treatment with zinc methionine (Met) or zinc oxide (ZO)
compared to a placebo on clinical curea in neonatal Holstein calves with diarrhea.
Treatmentb Enrollment
(n)
Clinical cure at exit
(n)
 ˇ SE Hazard ratio 95% CI P-value
Lower Upper
Placebo 24 21
Zinc Met  26 22 −0.091 0.306 0.91 0.50 1.66 0.766
ZO  23 22 0.339 0.308 1.40 0.77 2.57 0.272
et  = 80 m
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(a Clinical cure defined as normal fecal consistency for at least 24 h.
b Treatment: Placebo = zinc-free oral rehydration solution (ORS); zinc M
99.7  mg  of ZO).
Cox regression model results for clinical cure are
resented in Tables 3 and 4. Although there were no sig-
ificant differences in hazards of clinical cure between
he treatment groups, calves that were treated with ZO
ad 1.4 times higher hazard of a clinical cure at exit
fecal score = 1) compared to calves in the placebo group
P = 0.272; power = 5.3%). For clinical cure by pathogen at
nrollment, all 4 calves positive for E. coli K99 at enroll-
ent (2 in the placebo group, 1 in each of the zinc MET  and
O groups) attained clinical cure, hence a survival analy-
is was not possible. Although not significant, the hazard
atios comparing clinical cure in calves positive for Cryp-
osporidium spp. or coronavirus at enrollment when treated
ith ZO in comparison to a placebo were greater than 1
power = 66.1% and 5.2%, respectively). However, this was
ot the case for calves that tested positive for rotavirus at
nrollment in either zinc Met  or ZO groups (power = 5.1%).
.5. Microbiological cure
Results of logistic regression models for microbiological
ure are summarized in Tables 5 and 6. Although not sta-
istically significant, the odds of testing negative for all four
athogens at exit were 1.55 times higher in calves treated
ith zinc Met  compared to calves treated with a placebo
P = 0.455; power = 47.9%). For pathogen specific cure, all
alves that tested positive at enrollment for coronavirus
n = 37) or E. coli K99 (n = 4) tested negative at exit (fecal
core = 1 or 14 days of treatment). Similarly, out of the
6 calves that tested positive for rotavirus at enrollment
able 4
ox Regression model results from a double-blind block-randomized clinical trial
ompared to a placebo on clinical curea in neonatal Holstein calves with diarrhea
ELISA status at
enrollment
Treatmentb Enrollment (n) Clinical cure at
exit (n)
ˇ
Cryptosporidium
spp.
Placebo 5 5 R
Zinc Met  5 3 −
ZO  10 10 1
Coronavirus Placebo  15 12 R
Zinc Met  11 9 −
ZO  11 10 0
Rotavirus Placebo  11 11 R
Zinc Met  14 13 −
ZO  11 11 −
a Clinical cure defined as normal fecal consistency for at least 24 h.
b Treatment: Placebo = zinc-free oral rehydration solution (ORS); zinc Met  = 80 m
99.7  mg  of ZO).g of zinc/2 L of ORS (381.5 mg of zinc Met); ZO = 80 mg of zinc/2 L of ORS
only 2 tested positive at exit (fecal score = 1 or 14 days of
treatment). Hence, logistic regression analyses for micro-
biological cure in calves that tested positive for the latter
pathogens was  not possible. In contrast, calves that tested
positive for Cryptosporidium spp. at enrollment and were
treated with zinc Met  had 16 times higher odds of being
fecal ELISA negative at exit compared to the placebo group,
however this difference was  also not significant (P = 0.08;
power = 72.3%).
4. Discussion
Data collected from the current trial showed that a daily
zinc dose of 80 mg  did not result in zinc toxicosis or copper
or iron deficiency. The current trial results did not provide
evidence for a beneficial effect of either zinc Met  or ZO as
a treatment for diarrhea in neonatal Holstein calves. This
is in contrast to studies on infants that reported a signif-
icant reduction in diarrhea-associated mortality after oral
zinc supplementation (Bhandari et al., 2008; Bhutta et al.,
2000). The difference in findings between the pediatric tri-
als and our calf trial may  be explained by the differences
in pathogens or disease severity since pediatric research
was  conducted on diseased infants with more severe clin-
ical signs and a greater risk of mortality compared to
calves in our trial. Other explanations for the lack of sig-
nificant differences among the treatment groups may  be
due to a sub-therapeutic zinc dose (trial dose provided
80 mg  of available zinc/day), or a small sample size. Indeed,
 on the effect of treatment with zinc methionine (Met) or zinc oxide (ZO)
 by pathogen at enrollment.
 SE Hazard ratio 95% CI P-value
Lower Upper
eference
0.511 0.730 0.60 0.14 2.51 0.484
.249 0.716 3.49 0.86 14.18 0.081
eference
0.193 0.442 0.83 0.35 1.96 0.663
.196 0.435 1.22 0.52 2.86 0.652
eference
0.068 0.418 0.93 0.41 2.12 0.871
0.123 0.429 0.88 0.38 2.05 0.774
g of zinc/2 L of ORS (381.5 mg of zinc Met); ZO = 80 mg of zinc/2 L of ORS
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Table 5
Logistic regression model results from a double-blind block-randomized clinical trial on the effect of treatment with zinc methionine (Met) or zinc oxide
(ZO)  compared to a placebo on microbiological curea in neonatal Holstein calves with diarrhea.
Treatmentb Fecal ELISA positive
at enrollment (n)
Fecal ELISA
negative at exit (n)
 SE OR 95% C.I. P-value
Lower Upper
Placebo 23 9 Reference
Zinc Met 24 12 0.442 0.591 1.55 0.49 4.95 0.455
ZO  21 4 −1.01 0.701 0.37 0.09 1.45 0.152
9, Crypto
et  = 80 ma Microbiological cure defined as fecal ELISA test negative for E. coli K9
b Treatment: Placebo = zinc-free oral rehydration solution (ORS); zinc M
(99.7  mg  of ZO).
estimates of power analyses from the current data show
evidence of low sample size.
At exit, calves treated with zinc Met  had significantly
higher fecal and serum zinc concentrations compared to
the placebo treated group, however there were no signifi-
cant differences in liver zinc concentrations at exit among
the three treatment groups. Stratified analysis by dura-
tion of treatment (1–5, 6–10, or 11–14 days) showed that
calves on treatment for up to 10 days and supplemented
with zinc Met  had significantly higher fecal zinc concen-
trations compared to the placebo treated calves, but there
were no differences in liver or serum zinc concentrations
among the three groups (data not shown). Total zinc was
measured in feces (mg/kg DW), and thus we are not able
to differentiate between the different forms of zinc. It is
known that fecal excretion of zinc increases as the intake
of zinc increases in humans, so it is possible that zinc Met
was absorbed, metabolized to other forms of zinc, and
then excreted via the intestine and bile (Cousins, 1985;
Spencer et al., 1985). This trend did not continue for calves
treated for more than 10 days. Calves in the trial for more
than 10 days and supplemented with zinc Met  had signifi-
cantly higher serum and liver zinc concentrations than the
placebo treated calves. These findings are consistent with
the increased bioavailability of zinc Met  compared to ZO
(absorption coefficient of zinc Met  = 0.40 compared to 0.12
for ZO) reported by Cousins (1985).
It is known that the bovine fetus is completely depend-
ent on the placenta during gestation for supply of essential
trace elements (Hidiroglou and Knipfel, 1981). In addi-
tion, liver zinc mean (SEM) concentrations vary from 1110
(193) mg/kg DW during 120–170 days of gestation to
716 (385) mg/kg DW during 221–270 days of gestation
(Abdelrahman and Kincaid, 1993). The zinc concentration
of bovine colostrum and milk is 15 g/ml and 3–5 g/ml,
Table 6
Logistic regression model results from a double-blind block-randomized clinical 
(ZO)  compared to a placebo on microbiological curea in neonatal Holstein calves 
Treatmentb Cryptosporidium spp.
positiveat enrollment (n)
Cryptosporidium spp.
negative at exit (n)
Placebo 5 1 
Zinc  Met 5 4 
ZO  10 1 
a Microbiological cure defined as fecal ELISA test negative for E. coli K99, Crypto
b Treatment: Placebo = zinc-free oral rehydration solution (ORS); zinc Met  = 80 m
(99.7  mg  of ZO).sporidium spp., rotavirus, and coronavirus at exit from trial.
g of zinc/2 L of ORS (381.5 mg  of zinc Met); ZO = 80 mg  of zinc/2 L of ORS
respectively. In the current study, all calves were fed for-
mulated milk replacer containing 2.4 mg/kg zinc DW,  the
equivalent of 0.29 g zinc/ml as fed (Abdelrahman and
Kincaid, 1993). The National Research Council (NRC) daily
zinc recommendation for calves is 40 mg/kg of total diet.
There is a significant effect of age on liver zinc concentra-
tions in calves in that the liver zinc concentrations decrease
with time after birth (Puschner et al., 2004a). The low levels
found in colostrum and milk replacer may  reflect adequate
tissue reserves of zinc in the bovine neonate (Abdelrahman
and Kincaid, 1993; NRC, 2001). Thus if calves are born with
adequate zinc stores in the liver and do not require much
in the diet, our trial dose of 80 mg  of zinc/day was likely too
low to have an effect. At exit, trial calves treated with zinc
Met  had significantly higher fecal (P < 0.01) and serum zinc
(P = 0.02) concentrations compared to the placebo group.
Despite zinc Met  being more bioavailable, it was  excreted
in the feces. This further indicates that calves have ade-
quate zinc body stores and our trial dose may  have been
too low to have an effect.
The current trial’s zinc dose of 80 mg/day in Holstein
calves aged 1–22 days did not result in zinc toxicosis. It
is known that clinical signs and death from zinc toxicosis
can occur in pre-ruminant calves fed 700 g zinc/g (mg/kg)
diet for 30 days (Graham et al., 1987a). In previous stud-
ies where 3–38 day old male Holstein calves were fed
milk replacers containing 40, 200, 500, 700, or 1000 mg/kg
of zinc, weight gains, DM intakes, and feed efficiencies
were reduced at the 700 and 1000 mg/kg level (Jenkins
and Hidiroglou, 1991). The calves in the current trial were
being fed a formulated milk replacer made on the calf ranch
that contained 2.4 mg/kg zinc. The addition of an additional
80 mg  of zinc resulted in a total zinc level well below the
toxic dose of 700 g/g of zinc assuming they were fed 1
gallon or 3.79 kg of milk per day. Approximately, total zinc
trial on the effect of treatment with zinc methionine (Met) or zinc oxide
with diarrhea and Cryptosporidium spp. ELISA positive at enrollment.
 ˇ SE OR 95% C.I. P-value
Lower Upper
Reference
2.773 1.581 16.00 0.72 354.80 0.080
−0.811 1.537 0.44 0.02 9.03 0.598
sporidium spp., rotavirus, and coronavirus at exit from trial.
g of zinc/2 L of ORS (381.5 mg  of zinc Met); ZO = 80 mg  of zinc/2 L of ORS
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ntake level was (3.79 kg × 2.4 mg)  + 80 mg  = 89.1 mg.  Previ-
us research indicated that calves require anywhere from
 to 14 mg/kg of zinc in their total diet to maintain ade-
uate plasma levels, but that up to 40 mg/kg of dietary zinc
ay  be required according to the NRC (Herrick, 1974; NRC,
001). Thus, the therapeutic dose is not known for this age
f Holstein calves, and this information suggests that there
ay  be a wide range among tolerance, therapeutic, and
oxic levels.
An important finding of the current study was  that
alves treated with either zinc Met  or ZO did not experience
linical or laboratory evidence of zinc toxicity. The mean
SEM) liver zinc wet weight concentrations of the placebo,
inc Met, and ZO treated calves at exit were 145.3 (95.6),
79.1 (114.4), and 137.6 (72.3) mg/kg, respectively, which
re below reported mean liver zinc wet weight concentra-
ions of 345.7 (16.1) mg/kg in neonatal Holstein calves with
linical signs of zinc toxicosis (Graham et al., 1988). It has
een reported in calves up to one year of age, without clini-
al signs of zinc deficiency or toxicosis, that acceptable liver
inc concentrations range from 49 to 117 mg/kg wet  weight
Puschner et al., 2004a). Based on these data, calves in our
rial did not have liver zinc concentrations suggestive of
inc deficiency (24–28 mg/kg wet weight) or toxicosis, but
t is possible that there is a wide range of liver zinc concen-
rations during the first three weeks of life, from birth to
eaning, and from weaning to breeding age.
When supplementing zinc in the diet of calves, interac-
ion with other metals, especially copper and iron must be
onsidered (Graham et al., 1988). There were 70 calves that
ad measurable liver copper concentrations at exit from
he trial. The mean (SEM) liver copper wet weight concen-
rations for the placebo, zinc Met, and ZO treated calves
ere 175.6 (105.6), 143.5 (60.4), and 110.1 (62.0) mg/kg,
espectively. It has been reported that newborn calves
ithout clinical signs of copper deficiency or toxicosis can
e expected to have liver copper concentrations ranging
rom 62 to 125 mg/kg wet weight or 190 to 380 mg/kg DW
Puschner et al., 2004b). Calves in the placebo, zinc Met,
nd ZO treatment groups had mean liver copper DW val-
es higher than this range at exit, indicating that the zinc
upplementation did not cause a deficiency in liver copper
oncentrations.
In the current trial, calves treated with zinc Met  had
 mean daily gain of 40.24 g compared to a daily loss in
he other two treatment groups. The observations recorded
rom this trial do not prove that calves treated with zinc
et  tend to gain rather than lose weight but the direc-
ion of point estimates for weight change between groups
s worth further investigation. The sample size at the cur-
ent study permitted a power of 19.9% to detect significant
aily weight gain in the zinc MET  group compared to the
lacebo group. As discussed earlier, sample size determi-
ation for this study was based on a study in infants that
etected a statistically significant difference between chil-
ren with gastro-intestinal illness and healthy infants and
nfants with diseases other than diarrhea (Naveh et al.,
982). This approach may  be inappropriate for detecting
 significant difference in neonatal Holstein calves. Given
ur study findings, the sample size needed to detect a sta-
istically significant difference in mean daily weight change Medicine 112 (2013) 338– 347
between the placebo group (−66.88 g/day, SD 296.16) and
the zinc Met  group (40.24 g/day, SD 374.53) given a power
of 90% is 213 calves per group. Such a number can be easily
attained on most dairy or calf ranches in California.
Although the data collected did not prove a positive
association between ZO and clinical cure, calves supple-
mented with ZO had a higher hazard of a clinical cure
compared to the placebo. In addition, the hazard for clinical
cure in calves that tested positive for Cryptosporidium spp.
or coronavirus at enrollment when treated with ZO were
greater than the respective hazards in calves treated with
a placebo. With respect to microbiological cure, calves that
tested positive for Cryptosporidium spp. at enrollment and
treated with zinc Met  had 16 times higher odds of micro-
biological cure (being pathogen test negative at exit) than
calves in the placebo group. Given the magnitude of the
association (OR = 16) and it is respective power estimate of
72.3%, further studies are required to investigate the effect
of zinc Met  on microbiological prevention and cure from
cryptosporidiosis in dairy calves. The lethal dose (LD 50) for
such zinc formulation for different age groups would need
to be estimated through formal toxicity studies to guide
the dairy industry in the use of an optimal dose for zinc
therapeutic treatment in calf diarrhea to avoid accidental
intoxication.
The current study results are limited by the finding of
only clinically important differences between treatment
groups which were not statistically significant. Further-
more, the study was  conducted on a large calf ranch in
California which may  differ in preweaned calf manage-
ment on dairies. Important differences may  include less
variability in preweaned calf diets and more closely fol-
lowed standard protocols for calf health monitoring and
treatments. Despite such limitations, results of the current
double blind clinical trial show that there may  be a pos-
itive impact of zinc on calf health management including
decrease in use of antimicrobial drugs.
5. Conclusions
This is the first randomized clinical trial testing the
effect of a daily oral zinc supplementation in neonatal Hol-
stein calves with diarrhea. Data collected from the current
trial did not provide evidence for a beneficial effect of daily
oral 80 mg  of zinc as either zinc Met  or ZO treatment on
days to recovery, fecal consistency, or microbiological and
clinical cures in Holstein calves with diarrhea. A total daily
dose of 80 mg  of available zinc did not result in a zinc
toxicity or mineral deficiency. Although statistically not
significant, the current trial identified clinically important
differences in weight change during the course of diar-
rhea in calves and other potentially interesting contrasts
between effect of organic versus inorganic zinc formula-
tions on clinical and microbial cures in neonatal Holstein
calves which differed by pathogen.
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